サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1452961

造影剤の世界市場、2024-2031年

Global Contrast Media Market 2024-2031
出版日: | 発行: Orion Market Research | ページ情報: 英文 130 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.98円
造影剤の世界市場、2024-2031年
出版日: 2024年02月08日
発行: Orion Market Research
ページ情報: 英文 130 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の造影剤市場は、予測期間中にCAGR 6.5%の大幅な成長が見込まれています。造影剤（CM）は、画像中の体組織間の差異を強調するために医療画像診断技術で使用される化学物質です。世界市場を牽引しているのは、慢性疾患の増加、画像誘導による処置や診断に対する需要の高まり、造影剤の承認数の多さなどです。

造影剤の需要増に対応するため、主要企業は生産能力増強に投資しています。例えば、2022年11月、GEヘルスケアの医薬品診断事業は、ノルウェーのリンデスネスにある同社の原薬（API）サイトで製造能力を30.0％増強するために8,000万米ドルを投資すると発表しました。この投資は、臓器、血管、組織を疾患経路全体にわたって可視化するために、世界中のX線検査やコンピュータ断層撮影（CT）検査で使用されるヨード化造影剤に対する将来の大きな世界的需要に対応するためのGEヘルスケアの広範なコミットメントの一環です。

2023年11月に発表された科学論文によると、ヨウ素系造影剤の反復静脈内投与が早期胃がん患者の長期腎機能に及ぼす有害な影響が注目されています。こうした化学物質の副作用は、市場の成長を抑制する可能性があります。2024年1月、ケース・ウェスタン・リザーブ大学（CWRU）の科学者たちは、化学的な画像造影剤に代わる人工知能ベースの造影剤を開発するため、全米科学財団から4年間で112万5,000米ドルの助成金を獲得しました。彼らは、CT、MR、X線検査の際に、ガドリニウムなどの物質を注入することなく画像を強化する新しいアプローチを生み出したいと考えています。こうした新興国市場の開拓も、世界市場の成長に悪影響を及ぼす可能性があります。

セグメント別の展望

ヨード化造影剤が世界の造影剤市場で大きなシェアを占める

ヨード化造影剤はヨウ素を含む薬剤で、X線やCTスキャンなどの医療画像で血管や臓器を見る能力を高めるために患者に投与されます。ICM製品は静脈への注射、飲み薬としての経口投与、直腸投与が可能です。新たな適応症に対するFDA承認の高まりとともに、提供される利点のためにこれらの造影剤に対する需要が高いことが、この市場セグメントの高いシェアの主な要因となっています。例えば、2023年6月、Bayer社は、ヨードベースの造影剤であるUltravist（iopromide）-300,-370が造影マンモグラフィ（CEM）の適応で米国FDAから承認されたと発表しました。本製品は、マンモグラフィや超音波検査の補助として、成人乳房の既知または疑いのある病変を描出するために使用できます。

地域別展望

北米が世界市場で大きなシェアを占める

地域別市場シェアは、造影剤需要の増加と造影剤分野の研究開発への資金提供によって牽引されています。例えば、2022年10月、新興企業のInlighta Biosciences, LLCは、アルコール性および非アルコール性脂肪性肝疾患によって引き起こされる肝臓の瘢痕組織形成である肝線維化を検出するための磁気共鳴画像造影剤の開発を加速させるために、米国国立衛生研究所から助成金を授与されました。

この地域全体に主要企業が存在することが、この地域の市場成長をさらに後押ししています。例えば、2022年11月、GEヘルスケアは米国におけるGEヘルスケアブランドの造影剤注入器についてUlrich Medical社との契約を発表しました。CT motionマルチドーズシリンジレスインジェクターは、コンピュータ断層撮影（CT）画像処置用にヨウ素化造影剤を供給するもので、処置のセットアップ時間を短縮し、時間のかかる準備ステップを省くことで患者のスループットを向上させるとともに、患者の投与量の最適化を支援し、無駄な造影剤を削減します。

目次

第1章 レポート概要

  • 業界の現状分析と成長ポテンシャルの展望
  • 調査方法とツール
  • 市場内訳
    • セグメント別
    • 地域別

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向
    • 主な調査結果
    • 推奨事項
    • 結論

第3章 競合情勢

  • 主要企業分析
  • Bayer AG
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Bracco Diagnostic Inc.
    • 会社概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • GE Healthcare
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Guerbet Group
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • 主要戦略分析

第4章 市場セグメンテーション

  • 造影剤の世界市場：タイプ別
    • ヨード系造影剤
    • ガドリニウム系造影剤
    • マイクロバブル造影剤
    • バリウム系造影剤
  • 造影剤の世界市場：手技別
    • X線/CT
    • MRI
    • 超音波
  • 造影剤の世界市場：適応症別
    • 心血管疾患
    • 腫瘍
    • 消化器疾患
    • 神経疾患

第5章 地域別分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 世界のその他の地域

第6章 企業プロファイル

  • B. Braun Melsungen AG
  • Beijing Beilu Pharmaceutical Co. Ltd.
  • Borregaard
  • CONGRUENT PHARMACHEM PVT LTD
  • CR Double-Crane Pharmaceuticals Co., Ltd
  • DAIICHI SANKYO COMPANY, LTD.
  • Eisai Co., Ltd
  • FUJIFILM Corp.
  • HANA PHARM CO., LTD.
  • iMAX Diagnostic Imaging Limited
  • Jodas Expoim Pvt. Ltd.,
  • Lantheus Medical Imaging Inc.
  • Livealth Biopharma Pvt Ltd.
  • MEDTRON AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Radiology Bayer Australia Ltd
  • Rege Imaging & Cine Films Private Ltd.
  • Shanghai Xudong Haipu Pharmaceutical Co., Ltd
  • Spago Nanomedical AB
  • SQM SA
  • Subhra Pharma Pvt Ltd.
  • Taejoon Pharm
  • Trivitron Healthcare Pvt. Ltd.
  • ulrich GmbH & Co. KG
図表

LIST OF TABLES

  • 1.GLOBAL CONTRAST MEDIA MARKET RESEARCH AND ANALYSIS BY TYPE, 2023-2031 ($ MILLION)
  • 2.GLOBAL IODINATED CONTRAST MEDIA MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 3.GLOBAL GADOLINIUM-BASED CONTRAST MEDIA MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 4.GLOBAL MICROBUBBLE CONTRAST MEDIA MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 5.GLOBAL BARIUM-BASED CONTRAST MEDIA MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 6.GLOBAL CONTRAST MEDIA MARKET RESEARCH AND ANALYSIS BY PROCEDURE, 2023-2031 ($ MILLION)
  • 7.GLOBAL X-RAY/ COMPUTED TOMOGRAPHY BASED CONTRAST MEDIA MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 8.GLOBAL MAGNETIC RESONANCE IMAGING (MRI) BASED CONTRAST MEDIA MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 9.GLOBAL ULTRASOUND BASED CONTRAST MEDIA MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 10.GLOBAL CONTRAST MEDIA MARKET RESEARCH AND ANALYSIS BY INDICATION, 2023-2031 ($ MILLION)
  • 11.GLOBAL CONTRAST MEDIA IN CARDIOVASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 12.GLOBAL CONTRAST MEDIA IN ONCOLOGY MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 13.GLOBAL CONTRAST MEDIA IN GASTROINTESTINAL DISORDERS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 14.GLOBAL CONTRAST MEDIA IN NEUROLOGICAL DISORDERS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 15.GLOBAL CONTRAST MEDIA MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 16.NORTH AMERICAN CONTRAST MEDIA MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2031 ($ MILLION)
  • 17.NORTH AMERICAN CONTRAST MEDIA MARKET RESEARCH AND ANALYSIS BY TYPE, 2023-2031 ($ MILLION)
  • 18.NORTH AMERICAN CONTRAST MEDIA MARKET RESEARCH AND ANALYSIS BY PROCEDURE, 2023-2031 ($ MILLION)
  • 19.NORTH AMERICAN CONTRAST MEDIA MARKET RESEARCH AND ANALYSIS BY INDICATION, 2023-2031 ($ MILLION)
  • 20.EUROPEAN CONTRAST MEDIA MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2031 ($ MILLION)
  • 21. EUROPEAN CONTRAST MEDIA MARKET RESEARCH AND ANALYSIS BY TYPE, 2023-2031 ($ MILLION)
  • 22.EUROPEAN CONTRAST MEDIA MARKET RESEARCH AND ANALYSIS BY PROCEDURE, 2023-2031 ($ MILLION)
  • 23.EUROPEAN CONTRAST MEDIA MARKET RESEARCH AND ANALYSIS BY INDICATION, 2023-2031 ($ MILLION)
  • 24.ASIA- PACIFIC CONTRAST MEDIA MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2031 ($ MILLION)
  • 25.ASIA- PACIFIC CONTRAST MEDIA MARKET RESEARCH AND ANALYSIS BY TYPE, 2023-2031 ($ MILLION)
  • 26.ASIA- PACIFIC CONTRAST MEDIA MARKET RESEARCH AND ANALYSIS BY PROCEDURE, 2023-2031 ($ MILLION)
  • 27.ASIA- PACIFIC CONTRAST MEDIA MARKET RESEARCH AND ANALYSIS BY INDICATION, 2023-2031 ($ MILLION)
  • 28.REST OF THE WORLD CONTRAST MEDIA MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2031 ($ MILLION)
  • 29.REST OF THE WORLD CONTRAST MEDIA MARKET RESEARCH AND ANALYSIS BY TYPE, 2023-2031 ($ MILLION)
  • 30.REST OF THE WORLD CONTRAST MEDIA MARKET RESEARCH AND ANALYSIS BY PROCEDURE, 2023-2031 ($ MILLION)
  • 31.REST OF THE WORLD CONTRAST MEDIA MARKET RESEARCH AND ANALYSIS BY INDICATION, 2023-2031 ($ MILLION)

LIST OF FIGURES

  • 1.GLOBAL CONTRAST MEDIA MARKET RESEARCH AND ANALYSIS BY TYPE, 2023 VS 2031 (%)
  • 2.GLOBAL IODINATED CONTRAST MEDIA MARKET RESEARCH AND ANALYSIS BY REGION, 2023 VS 2031 (%)
  • 3.GLOBAL GADOLINIUM-BASED CONTRAST MEDIA MARKET RESEARCH AND ANALYSIS BY REGION, 2023 VS 2031 (%)
  • 4.GLOBAL MICROBUBBLE CONTRAST MEDIA MARKET RESEARCH AND ANALYSIS BY REGION, 2023 VS 2031 (%)
  • 5.GLOBAL BARIUM-BASED CONTRAST MEDIA MARKET RESEARCH AND ANALYSIS BY REGION, 2023 VS 2031 (%)
  • 6.GLOBAL CONTRAST MEDIA MARKET RESEARCH AND ANALYSIS BY PROCEDURE, 2023 VS 2031 (%)
  • 7.GLOBAL X-RAY/ COMPUTED TOMOGRAPHY BASED CONTRAST MEDIA MARKET RESEARCH AND ANALYSIS BY REGION, 2023 VS 2031 (%)
  • 8.GLOBAL MAGNETIC RESONANCE IMAGING (MRI) BASED CONTRAST MEDIA MARKET RESEARCH AND ANALYSIS BY REGION, 2023 VS 2031 (%)
  • 9.GLOBAL ULTRASOUND BASED CONTRAST MEDIA MARKET RESEARCH AND ANALYSIS BY REGION, 2023 VS 2031 (%)
  • 10.GLOBAL CONTRAST MEDIA MARKET RESEARCH AND ANALYSIS BY INDICATION, 2023 VS 2031 (%)
  • 11.GLOBAL CONTRAST MEDIA IN CARDIOVASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2023 VS 2031 (%)
  • 12.GLOBAL CONTRAST MEDIA IN ONCOLOGY MARKET RESEARCH AND ANALYSIS BY REGION, 2023 VS 2031 (%)
  • 13.GLOBAL CONTRAST MEDIA IN GASTROINTESTINAL DISORDERS MARKET RESEARCH AND ANALYSIS BY REGION, 2023 VS 2031 (%)
  • 14.GLOBAL CONTRAST MEDIA IN NEUROLOGICAL DISORDERS MARKET RESEARCH AND ANALYSIS BY REGION, 2023 VS 2031 (%)
  • 15.GLOBAL CONTRAST MEDIA MARKET RESEARCH AND ANALYSIS BY REGION, 2023 VS 2031 (%)
  • 16.US CONTRAST MEDIA MARKET SIZE, 2023-2031 ($ MILLION)
  • 17.CANADA CONTRAST MEDIA MARKET SIZE, 2023-2031 ($ MILLION)
  • 18.UK CONTRAST MEDIA MARKET SIZE, 2023-2031 ($ MILLION)
  • 19.FRANCE CONTRAST MEDIA MARKET SIZE, 2023-2031 ($ MILLION)
  • 20.GERMANY CONTRAST MEDIA MARKET SIZE, 2023-2031 ($ MILLION)
  • 21.ITALY CONTRAST MEDIA MARKET SIZE, 2023-2031 ($ MILLION)
  • 22.SPAIN CONTRAST MEDIA MARKET SIZE, 2023-2031 ($ MILLION)
  • 23.REST OF EUROPE CONTRAST MEDIA MARKET SIZE, 2023-2031 ($ MILLION)
  • 24.INDIA CONTRAST MEDIA MARKET SIZE, 2023-2031 ($ MILLION)
  • 25.CHINA CONTRAST MEDIA MARKET SIZE, 2023-2031 ($ MILLION)
  • 26.JAPAN CONTRAST MEDIA MARKET SIZE, 2023-2031 ($ MILLION)
  • 27.SOUTH KOREA CONTRAST MEDIA MARKET SIZE, 2023-2031 ($ MILLION)
  • 28.REST OF ASIA-PACIFIC CONTRAST MEDIA MARKET SIZE, 2023-2031 ($ MILLION)
  • 29.REST OF THEWORLD CONTRAST MEDIA MARKET SIZE, 2023-2031 ($ MILLION)
目次
Product Code: OMR2028176

Global Contrast Media Market Size, Share & Trends Analysis Report by Type (Iodinated Contrast Media, Gadolinium-based Contrast Media, Microbubble Contrast Media, and Barium-based Contrast Media), by Procedure (X-Ray/ Computed Tomography, Magnetic Resonance Imaging (MRI), and Ultrasound), by Indication (Cardiovascular Diseases, Oncology, Gastrointestinal Disorders, and Neurological Disorders) Forecast Period (2024-2031)

Global contrast media market is anticipated to grow at a considerable CAGR of 6.5% during the forecast period. Contrast media (CM) are chemical substances used in medical imaging techniques to enhance the differences between body tissues in images. The global market is driven by the increasing incidences of chronic diseases, rising demand for image-guided procedures and diagnostics, and a large number of approvals for contrast agents.

To meet the growing demand for contrast agents, key players are investing in their production capacity expansion. For instance, in November 2022, GE Healthcare's Pharmaceutical Diagnostics business announced an $80 million investment to increase manufacturing capacity by 30.0% at its Active Pharmaceutical Ingredients (API) site in Lindesnes, Norway. The investment is part of GE Healthcare's broader commitment to address significant future global demand for iodinated contrast media, used in X-ray and Computed Tomography (CT) procedures around the world to enhance visualization of organs, blood vessels, and tissues across disease pathways.

According to a scientific published in November 2023, the harmful effect of repetitive intravenous iodinated contrast media administration has been noticed on the long-term renal function of patients with early gastric cancer. Such side effects of these chemicals may restrain their market growth. In January 2024, Scientists with Case Western Reserve University (CWRU) scored a four-year, $1.125 million grant from the National Science Foundation to develop an artificial intelligence-based alternative to chemical imaging contrast agents. They hope to create a new approach during CT, MR, and X-ray exams, enhancing images without injecting substances such as gadolinium. Such developments may also have a negative impact on the growth of the global market.

Segmental Outlook

The global contrast media market is segmented based on type, procedure, and indication. Based on type, the market is segmented into iodinated contrast media, gadolinium-based contrast media, microbubble contrast media, and barium-based contrast media. Based on procedure, the market is segmented into X-ray/ Computed Tomography, Magnetic Resonance Imaging (MRI), and ultrasound. Based on indication, the market is segmented into cardiovascular diseases, oncology, gastrointestinal disorders, and neurological disorders.

Iodinated Contrast Media Held a Considerable Share in the Global Contrast Media Market

Iodinated contrast media are drugs containing iodine that are given to patients to enhance the ability to see blood vessels and organs on medical images such as X-rays or computed tomography (CT) scans. ICM products can be given as injections into the veins, by mouth as a drink, or rectally. The high demand for these contrast media owing to its offered advantages along with rising FDA approvals for its new indications is a key contributor to the high share of this market segment. For instance, in June 2023, Bayer announced today that Ultravist (iopromide)-300, -370, its iodine-based contrast agent, has been approved by the US FDA for contrast-enhanced mammography (CEM) - making it the only contrast agent approved for this indication. The product can be used to visualize known or suspected lesions of the breast in adults, as an adjunct to mammography and/or ultrasound.

Regional Outlooks

The global contrast media market is further segmented based on geography, including North America (the US and Canada), Europe (Italy, Spain, Germany, France, and others), Asia-Pacific (India, China, Japan, South Korea, and others), and the Rest of the World (the Middle East & Africa and Latin America). Asia-Pacific is anticipated to exhibit considerable growth in the global market.

North America Held Considerable Share in the Global Market

The regional market share is driven by growing demand for contrast media and funding for R&D in the field of contrast media. For instance, in October 2022, Inlighta Biosciences, LLC, a start-up company was awarded a National Institute of Health grant to accelerate the development of a magnetic resonance imaging contrast agent to detect liver fibrosis, formation of scar tissue in the liver caused by alcoholic and non-alcoholic fatty liver disease.

The presence of key players across the region is further aiding the regional market growth. For instance, in November 2022, GE Healthcare announced an agreement with Ulrich Medical for a GE Healthcare branded contrast media injector in the US. The CT motion multi-dose syringeless injector, which delivers iodinated contrast media for Computed Tomography (CT) imaging procedures, reduces procedure setup time and increases patient throughput by eliminating time-consuming preparation steps while helping to optimize patient dosing and reducing wasted contrast media.

Market Players Outlook

The major companies serving the global contrast media market include Bayer AG, Bracco Diagnostic Inc., GE Healthcare, Guerbet Group, and Lantheus Medical Imaging Inc. among others. The market players are considerably contributing to the market growth by the adoption of various strategies, including mergers and acquisitions, partnerships, collaborations, distribution network expansion, and production capacity expansion to stay competitive in the market. For instance, in October 2022, GE Healthcare's Pharmaceutical Diagnostics business announced a long-term agreement with Chile-based mining company, Sociedad Quimica y Minera de Chile S.A. (SQM), to secure its supply of iodine, a key ingredient for contrast media products used in X-Ray and Computed Tomography (CT) procedures globally. The agreement will see SQM increase the supply of iodine raw material year-on-year and is part of GE Healthcare's broader commitment and investment plan to enable the production of 30 million more patient doses of iodinated contrast media annually by 2025.

The Report Covers:

  • Market value data analysis of 2023 and forecast to 2031.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global contrast media market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1.Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1.Research Methods and Tools
  • 1.2.Market Breakdown
    • 1.2.1.By Segments
    • 1.2.2.By Region

2.Market Overview and Insights

  • 2.1.Scope of the Report
  • 2.2.Analyst Insight & Current Market Trends
    • 2.2.1.Key Findings
    • 2.2.2.Recommendations
    • 2.2.3.Conclusion

3.Competitive Landscape

  • 3.1.Key Company Analysis
  • 3.2.Bayer AG
    • 3.2.1.Overview
    • 3.2.2.Financial Analysis
    • 3.2.3.SWOT Analysis
    • 3.2.4.Recent Developments
  • 3.3.Bracco Diagnostic Inc.
    • 3.3.1.Overview
    • 3.3.2.Financial Analysis
    • 3.3.3.SWOT Analysis
    • 3.3.4.Recent Developments
  • 3.4.GE Healthcare
    • 3.4.1.Overview
    • 3.4.2.Financial Analysis
    • 3.4.3.SWOT Analysis
    • 3.4.4.Recent Developments
  • 3.5.Guerbet Group
    • 3.5.1.Overview
    • 3.5.2.Financial Analysis
    • 3.5.3.SWOT Analysis
    • 3.5.4.Recent Developments
  • 3.6.Key Strategy Analysis

4.Market Segmentation

  • 4.1.Global Contrast Media Market by Type
    • 4.1.1.Iodinated Contrast Media
    • 4.1.2.Gadolinium-based Contrast Media
    • 4.1.3.Microbubble Contrast Media
    • 4.1.4.Barium-based Contrast Media
  • 4.2.Global Contrast Media Market by Procedure
    • 4.2.1.X-Ray/ Computed Tomography
    • 4.2.2.Magnetic Resonance Imaging (MRI)
    • 4.2.3.Ultrasound
  • 4.3.Global Contrast Media Market by Indication
    • 4.3.1.Cardiovascular Diseases
    • 4.3.2.Oncology
    • 4.3.3.Gastrointestinal Disorders
    • 4.3.4.Neurological Disorders

5.Regional Analysis

  • 5.1.North America
    • 5.1.1.United States
    • 5.1.2.Canada
  • 5.2.Europe
    • 5.2.1.UK
    • 5.2.2.Germany
    • 5.2.3.Italy
    • 5.2.4.Spain
    • 5.2.5.France
    • 5.2.6.Rest of Europe
  • 5.3.Asia-Pacific
    • 5.3.1.China
    • 5.3.2.India
    • 5.3.3.Japan
    • 5.3.4.South Korea
    • 5.3.5.Rest of Asia-Pacific
  • 5.4.Rest of the World

6.Company Profiles

  • 6.1.B. Braun Melsungen AG
  • 6.2.Beijing Beilu Pharmaceutical Co. Ltd.
  • 6.3.Borregaard
  • 6.4.CONGRUENT PHARMACHEM PVT LTD
  • 6.5.CR Double-Crane Pharmaceuticals Co., Ltd
  • 6.6.DAIICHI SANKYO COMPANY, LTD.
  • 6.7.Eisai Co., Ltd
  • 6.8.FUJIFILM Corp.
  • 6.9.HANA PHARM CO., LTD.
  • 6.10.iMAX Diagnostic Imaging Limited
  • 6.11.Jodas Expoim Pvt. Ltd.,
  • 6.12.Lantheus Medical Imaging Inc.
  • 6.13.Livealth Biopharma Pvt Ltd.
  • 6.14.MEDTRON AG
  • 6.15.Otsuka Pharmaceutical Co., Ltd.
  • 6.16.Radiology Bayer Australia Ltd
  • 6.17.Rege Imaging & Cine Films Private Ltd.
  • 6.18.Shanghai Xudong Haipu Pharmaceutical Co., Ltd
  • 6.19.Spago Nanomedical AB
  • 6.20.SQM SA
  • 6.21.Subhra Pharma Pvt Ltd.
  • 6.22.Taejoon Pharm
  • 6.23.Trivitron Healthcare Pvt. Ltd.
  • 6.24.ulrich GmbH & Co. KG